Title: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study
Authors: Ardon, Hilko
Van Gool, Stefaan
Lopes, Isabel Spencer
Maes, Wim
Sciot, Raphael
Wilms, Guy
Demaerel, Philippe
Bijttebier, Patricia
Claes, Laurence
Goffin, Jan
Van Calenbergh, Frank
De Vleeschouwer, Steven # ×
Issue Date: Feb-2010
Publisher: Springer Netherlands
Series Title: Journal of Neuro-Oncology vol:99 issue:2 pages:261-272
Abstract: Despite resection, radiochemotherapy, and maintenance temozolomide chemotherapy (TMZm), the prognosis of patients with glioblastoma multiforme (GBM) remains poor. We integrated immunotherapy in the primary standard treatment for eight pilot adult patients (median age 50 years) with GBM, to assess clinical and immunological feasibility and toxicity in preparation of a phase I/II protocol HGG-2006. After maximum, safe resection, leukapheresis was performed before radiochemotherapy, and four weekly vaccinations with autologous GBM lysate-loaded monocyte-derived dendritic cells were given after radiochemotherapy. Boost vaccines with lysates were given during TMZm. During the course of vaccination, immunophenotyping showed a relative increase in CD8+CD25+ cells in six of the seven patients, complying with the prerequisites for implementation of immunotherapy in addition to postoperative radiochemotherapy. In five patients, a more than twofold increase in tumor antigen-reacting IFN-gamma-producing T cells on Elispot was seen at the fourth vaccination compared with before vaccination. In three of these five patients this more than twofold increase persisted after three cycles of TMZm. Quality of life during vaccination remained excellent. Progression-free survival at six months was 75%. Median overall survival for all patients was 24 months (range: 13-44 months). The only serious adverse event was an ischemic stroke eight months postoperatively. We conclude that tumor vaccination, fully integrated within the standard primary postoperative treatment for patients with newly diagnosed GBM, is feasible and well tolerated. The survival data were used to power a currently running phase I/II trial.
ISSN: 0167-594X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Pediatric Immunology
Clinical Psychology
Research Group Experimental Neurosurgery and Neuroanatomy
Translational Cell & Tissue Research
Translational MRI (+)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Ardon_van Gool_Claes_2010.pdf Published 123KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science